Kishi H - Search Results

1

Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.

Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M. Kikuno N, et al. Among authors: kishi h. Cancer Res. 2004 Oct 15;64(20):7526-32. doi: 10.1158/0008-5472.CAN-04-0996. Cancer Res. 2004. PMID: 15492279

2

Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.

Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H. Urakami S, et al. Among authors: kishi h. J Urol. 2002 Dec;168(6):2444-50. doi: 10.1016/S0022-5347(05)64164-X. J Urol. 2002. PMID: 12441936 Clinical Trial.

3

The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.

Kikuno N, Yoshino T, Urakami S, Shigeno K, Kishi H, Hata K, Shiina H, Igawa M. Kikuno N, et al. Among authors: kishi h. Anticancer Res. 2003 Mar-Apr;23(2B):1305-12. Anticancer Res. 2003. PMID: 12820387

4

Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.

Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Kishi H, et al. J Urol. 2004 May;171(5):1855-60. doi: 10.1097/01.ju.0000120317.88372.03. J Urol. 2004. PMID: 15076293

5

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.

Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Urakami S, et al. Among authors: kishi h. Urology. 2005 Mar;65(3):543-8. doi: 10.1016/j.urology.2004.10.033. Urology. 2005. PMID: 15780373

6

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.

Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Kikuno N, et al. Among authors: kishi h. Eur Urol. 2007 May;51(5):1252-8. doi: 10.1016/j.eururo.2006.12.030. Epub 2006 Dec 26. Eur Urol. 2007. PMID: 17208356 Clinical Trial.

7

[Acid phosphatase].

Kishi H, Igawa M. Kishi H, et al. Nihon Rinsho. 2004 Nov;62 Suppl 11:365-7. Nihon Rinsho. 2004. PMID: 15628418 Japanese. No abstract available.

8

CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.

Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. Zhao H, et al. Among authors: kishi h. Cancer. 2005 Jul 1;104(1):44-52. doi: 10.1002/cncr.21135. Cancer. 2005. PMID: 15895377 Free article.

9

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.

Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. Urakami S, et al. Among authors: kishi h. Clin Cancer Res. 2006 Jan 15;12(2):383-91. doi: 10.1158/1078-0432.CCR-05-1344. Clin Cancer Res. 2006. PMID: 16428476

10

Usefulness of an immunochromatographical assay, PSA Rapid Test as a primary screening test for prostate cancer.

Shigeno K, Arichi N, Yoneda T, Kishi H, Shiina H, Igawa M. Shigeno K, et al. Among authors: kishi h. Int Urol Nephrol. 2006;38(3-4):565-9. doi: 10.1007/s11255-006-0086-2. Epub 2006 Nov 16. Int Urol Nephrol. 2006. PMID: 17111081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

600 results

Search Page

Filters